Cidara Therapeutics 株価情報 (NASDAQ: CDTX)

最新ニュース Cidara Therapeutics (NASDAQ:CDTX) 株価情報

CIDARA THERAPEUTICS INC

Cidara Therapeutics

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Cidara Therapeutics Inc

Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>), a biotechnology company using its proprietary Cloudbreak&#xAE;&nbsp;platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced participation in the "Other pharmaceuticals as preventive tools" panel at a World Health Organization (WHO) global meeting on H5N1 influenza preparedness and response. The meeting, titled "What research is important to prepare and respond to H5N1 influenza outbreaks," will be held virtually on March 19, 2025, from 1:00-7:15pm Central European Time (CET)/5:00-11:15am Pacific Time (PT), and the panel discussion will take place from 6:30-7:00 pm CET/10:30-11:00am PT.

Biotech

News

General

CDTX

Cidara Therapeutics Announces Participation In WHO Panel On H5N1 Influenza Preparedness And Response, Discussing Pharmaceuticals As Preventive Tools On March 19, 2025

Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>), a biotechnology company using its proprietary Cloudbreak&#xAE;&nbsp;platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming presentations at the 38th International Conference on Antiviral Research (ICAR). The conference takes place from March 17-21, 2025 in Las Vegas, Nevada. Cidara's presentations will highlight the study design, demographic information, and preliminary safety data from the ongoing Phase 2b NAVIGATE trial of CD388, as well as dose optimization models for evaluation of CD388 in a Phase 3 study.
Presentation details:
Title: NAVIGATE: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Dose-ranging Study to Evaluate the Efficacy and Safety of CD388, a Novel Long-acting Antiviral Conjugate, for Prevention of Influenza in Subjects not at Risk for Influenza Complications

Cidara Therapeutics Announces 2 Presentations On CD388 In Influenza At ICAR 2025

Key Findings
<ul>
<li>The publication describes CD388 and its potential for universal activity across influenza A and B viruses in cellular and animal models.
<ul>
<li>Administration of CD388 resulted in the following:
<ul>
<li>Potent, universal activity against all influenza A and B virus strains, including high pathogenicity strains like H5N1, also known as avian influenza or bird flu, and strains that are resistant to approved neuraminidase inhibitors</li>
<li>Low potential for resistance development</li>
<li>Efficacy at similar exposures in immune-competent and immune-compromised lethal challenge models in mice demonstrating that efficacy is driven predominantly by the intrinsic antiviral activity of CD388</li>
</ul>
</li>
</ul>
</li>
</ul>
CD388 is currently under clinical evaluation in the ~5000 patient Phase 2b NAVIGATE trial, evaluating CD388 for the single-dose prevention of seasonal influenza in healthy unvaccinated adult subjects.

Health Care

Cidara Therapeutics Announced The Publication Of Preclinical Data Assessing CD388, The Company's Influenza Drug-fc Conjugate, In The Peer-reviewed Scientific Journal Nature Microbiology

Citizens Capital Markets analyst Roy Buchanan initiates coverage on Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Market Outperform rating and announces Price Target of $46.

Price Target

Initiation

Analyst Ratings

Citizens Capital Markets Initiates Coverage On Cidara Therapeutics with Market Outperform Rating, Announces Price Target of $46

HC Wainwright &amp; Co. analyst Ed Arce maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy and raises the price target from $24 to $35.

HC Wainwright & Co. Maintains Buy on Cidara Therapeutics, Raises Price Target to $35

Needham analyst Joseph Stringer reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy and maintains $35 price target.

Reiteration

Needham Reiterates Buy on Cidara Therapeutics, Maintains $35 Price Target

Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) reported quarterly losses of $(5.37) per share which missed the analyst consensus estimate of $(3.62) by 48.34 percent. This is a 656.34 percent decrease over losses of $(0.71) per share from the same period last year.

Earnings

Earnings Misses

Cidara Therapeutics Q4 2024 GAAP EPS $(5.37) Misses $(3.62) Estimate

Management

Cidara Therapeutics Appoints Frank Karbe as CFO, Effective February 24, 2025

Cantor Fitzgerald analyst Eric Schmidt assumes Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Overweight rating.

Cantor Fitzgerald Assumes Cidara Therapeutics at Overweight

RBC Capital analyst Gregory Renza initiates coverage on Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Outperform rating and announces Price Target of $34.

RBC Capital Initiates Coverage On Cidara Therapeutics with Outperform Rating, Announces Price Target of $34

WBB Securities analyst Stephen Brozak maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Strong Buy and raises the price target from $40 to $45.

WBB Securities Maintains Strong Buy on Cidara Therapeutics, Raises Price Target to $45

Cidara Therapeutics Completes Enrollment Of Its Phase 2b NAVIGATE Trial Evaluating CD388 In The Prevention Of Seasonal Influenza

<h3>Gainers</h3>
<ul>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares moved upwards by 71.4% to $1.68 during Thursday's pre-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) stock rose 55.36% to $0.14. The market value of their outstanding shares is at $14.7 million. </li>
<li>Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares rose 28.96% to $19.5. The market value of their outstanding shares is at $137.4 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) stock rose 27.46% to $75.55. The company's market cap stands at $548.9 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock increased by 16.88% to $4.5. The market value of their outstanding shares is at $65.3 million. </li>
<li>DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) stock increased by 14.1% to $0.89. The market value of their outstanding shares is at $30.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pyxis Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) stock fell 43.5% to $2.16 during Thursday's pre-market session. The company's market cap stands at $128.3 million. </li>
<li>Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) shares declined by 27.23% to $4.49. The market value of their outstanding shares is at $303.4 million. </li>
<li>Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) stock decreased by 25.52% to $11.85. The company's market cap stands at $921.5 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) stock decreased by 22.42% to $0.42. The company's market cap stands at $33.8 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock declined by 20.0% to $0.27. The market value of their outstanding shares is at $3.8 million. </li>
<li>Assembly Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>) stock fell 11.06% to $13.36. The market value of their outstanding shares is at $84.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ASMB

BDRX

BLRX

CATX

DRIO

KURA

PYXS

SLXN

SMLR

WORX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

WIIM

Cidara Therapeutics shares are trading higher. The company announced a $105 million private placement.

Cidara Therapeutics shares are trading lower after the company announced a $105 million private placement.

Cidara Therapeutics Secures $105M In Private Placement; Closing Expected November 25, 2024

HC Wainwright &amp; Co. analyst Ed Arce reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy and maintains $24 price target.

HC Wainwright & Co. Reiterates Buy on Cidara Therapeutics, Maintains $24 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Guggenheim analyst Seamus Fernandez initiated coverage on Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy rating and announced a price target of $33. Cidara Therapeutics shares closed at $13.11 on Thursday. <a href="https://www.benzinga.com/quote/cdtx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Leonid Timashev initiated coverage on Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with an Outperform rating and announced a price target of $80. Cytokinetics shares closed at $55.84 on Thursday. <a href="https://www.benzinga.com/quote/cytk/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. analyst Sudan Loganathan initiated coverage on Immunome, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) with an Overweight rating and announced a price target of $30. Immunome shares closed at $12.54 on Thursday. <a href="https://www.benzinga.com/quote/imnm/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock</a>.</li>
<li>Jefferies analyst Dennis Ding initiated coverage on Inhibikase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) with a Buy rating and announced a price target of $8. Inhibikase Therapeutics shares closed at $2.78 on Thursday. <a href="https://www.benzinga.com/quote/ikt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Ben Shelley initiated coverage on Flutter Entertainment plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Buy rating and announced a price target of $306. Flutter Entertainment shares closed at $237.98 on Thursday. <a href="https://www.benzinga.com/quote/flut/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CYTK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="544" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-1024x544.png" alt="" class="wp-image-637640" style="width:627px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-1024x544.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92.png 1237w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

CYTK

FLUT

IMNM

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Guggenheim analyst Seamus Fernandez initiates coverage on Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy rating and announces Price Target of $33.

Guggenheim Initiates Coverage On Cidara Therapeutics with Buy Rating, Announces Price Target of $33

Financing

Press Releases

Cidara Therapeutics Announces $105 Million Private Placement

Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza

Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology

Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025

Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response

Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Cidara Therapeutics

ニュース

最新ニュース Cidara Therapeutics (NASDAQ:CDTX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル